Breast Cancer Coverage from Every Angle
Advertisement
Advertisement

William J. Gradishar, MD, on Hormone-Sensitive Breast Cancer: Guideline Updates

Posted: Friday, March 30, 2018

William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses updates to the NCCN recommendations on the efficacy, safety, and utility of HER2-targeted treatments in the adjuvant setting for early-stage and advanced breast cancers.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.